Tuberculosis Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
June 15th, 2009
CEL-SCI Corporation (NYSE AMEX: CVM) announced that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas. The investigators presented data that showed that blood cells from immunized mice produced gamma interferon in response to the vaccine, while the blood...
Source: Tuberculosis Week (2009-06-15)
|
